What are the regulations and guidelines for compensation in clinical trials in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Compensation for Clinical Trials in India: Regulations Under New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules (NDCTR) 2019 established a comprehensive framework for compensation in clinical trials in India, mandating sponsors to provide compensation for trial-related injuries or deaths and free medical management for all adverse events.

Legal Framework and Governing Authority

  • The New Drugs and Clinical Trials Rules 2019 serve as the primary regulatory framework for clinical trials in India, with Chapter VI specifically addressing compensation related to injury and death 1.
  • The Central Licensing Authority (CLA), represented by the Drug Controller General of India (DCGI), serves as the governing authority for clinical trial regulations 1.
  • These regulations aim to protect research participants while maintaining India's position as a clinical research destination 2.

When Compensation is Required

  • Compensation is mandatory if injury or death occurs during clinical trials, bioavailability studies, or bioequivalence studies 1.
  • Compensation must be provided for Serious Adverse Events (SAEs) that are related to the trial 1.
  • The sponsor is responsible for providing both compensation and free medical management for trial-related injuries 2.

Types of Injuries Covered for Compensation

  • Adverse reactions to the investigational product 1.
  • Violations of protocol or negligence by the sponsor or investigator 1.
  • Injuries resulting from the use of placebo in placebo-controlled trials 1.
  • Injuries due to concomitant non-standard medications used in the trial 1.
  • Injuries to a child in utero due to parent's participation in a trial 1.
  • Injuries resulting from trial-related procedures 1.

Compensation Formula

For Death

  • The compensation formula for death follows this structure: Compensation = [B] × [F] × [R], where:
    • [B] = Base amount (₹8,00,000)
    • [F] = Age factor (as per Workmen Compensation Act)
    • [R] = Risk factor (based on severity of disease, ranging from 0.5 to 4) 3.
  • The minimum compensation is ₹8 lakh, while the maximum can reach ₹73.6 lakh depending on age and risk factors 3.

For Injury/Disability

  • For permanent disability: Compensation = [D] × [C], where:
    • [D] = Percentage of disability
    • [C] = Compensation amount calculated for death 3.
  • For congenital anomalies or birth defects: ₹4 lakh plus medical management 3.
  • For reversible SAEs: Compensation is calculated based on the duration and severity of the adverse event 3.

Reporting and Compensation Process

  • Investigators must report SAEs within 24 hours to the DCGI, sponsor, and Ethics Committee 1.
  • An Independent Expert Committee reviews the cause and recommends appropriate compensation 1.
  • The sponsor must pay the compensation within 30 days from the order 1.

Role of Ethics Committees

  • Ethics Committees (ECs) play a crucial role in safeguarding participants' rights, safety, and well-being 1.
  • ECs must review and recommend compensation for SAEs within 21 days 1.
  • They are responsible for approving trial protocols and ensuring ethical compliance throughout the study 1.
  • The EC must be informed of all protocol amendments and serious or unexpected adverse events occurring during the trial 4.

Limitations of Compensation

  • No compensation is provided for failure of the drug to produce therapeutic benefit 5.
  • No compensation is required for injury caused by comparator drugs or licensed products used for comparison 5.
  • No compensation is given for contributory negligence by trial subjects or third parties 5.
  • No compensation is provided if the injury results from protocol deviation by the participant 5.

Recent Developments and Challenges

  • Economic changes since the formula was established in 2013 have eroded the value of compensation amounts, suggesting a need for review 3.
  • There are ongoing concerns about interpretation and implementation of these guidelines that need to be addressed for clarity 2.
  • Training of Ethics Committee members and other stakeholders remains a critical but inadequately defined area in the NDCTR 3.

Key Challenges in Implementation

  • Ensuring sponsor compliance with compensation rules 2.
  • Maintaining transparency with trial participants about their rights 2.
  • Ensuring timely reporting by investigators and sponsors for quick resolution of compensation claims 1.
  • Balancing the interests of all stakeholders while protecting research participants 2.

References

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

New Drugs and Clinical Trial Rules 2019, What is New? Our Views from Ethical Perspective.

The Journal of the Association of Physicians of India, 2019

Related Questions

What is the framework for compensating participants in clinical trials in India under the New Drugs and Clinical Trials Rules, 2019 (Central Drugs Standard Control Organization (CDSCO))?
What is the framework for compensating clinical trial participants in India under the New Drugs and Clinical Trials Rules, 2019 (Central Drugs Standard Control Organization (CDSCO))?
What is the framework for compensation in clinical trials in India under the New Drugs and Clinical Trials Rules (NDCTR), 2019?
What is the framework for compensating clinical trial participants in India who experience trial-related injury or death?
What is the compensation formula for injury or death in clinical trials in India under the New Drugs and Clinical Trials Rules, 2019?
Does administering acetaminophen (paracetamol) after spinal anesthesia prolong its duration?
What is the role of Teicoplanin (glycopeptide antibiotic) in treating Methicillin-Sensitive Staphylococcus aureus (MSSA) infections?
What is the recommended treatment for constipation using Laxopeg (polyethylene glycol)?
What is the difference between Euthyrox (levothyroxine), Medithyrox (levothyroxine), and Tirosint (levothyroxine) in the treatment of hypothyroidism?
What pain medication is suitable for a patient with ileus and hypotension?
How is Central Venous Pressure (CVP) monitored in the Intensive Care Unit (ICU)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question